Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 01, 2022 22:31 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech报告2021年第四季度和全年财务业绩并通报企业最新情况

- 该年度继续执行临床开发项目并不断累积越来越多的在多个高价值的适应症中使用Ampligen®的积极数据 - 公司预计将继续推进以肿瘤为重点的产品研发管线，并有望在2022年实现多个临床和监管价值驱动的里程碑 - 依托强劲的资产负债表执行战略，预计现金可支持到2023年的运营和临床开发项目佛罗里达州奥卡拉, April 02, 2022 (GLOBE NEWSWIRE) -- AIM...
March 31, 2022 16:05 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

- Year marked by continued execution across clinical development programs and the continued establishment of a growing body of positive data with Ampligen® in multiple high-value indications -...
March 28, 2022 07:35 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Abstract Accepted for Presentation at 15th Annual IHPBA World Congress

OCALA, Fla., March 28, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
March 24, 2022 10:10 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Abstract Entitled, Negative Impact of Paclitaxel on Human Breast Tumor Microenvironment and Its Reversal by the Combination of Interferon-α with TLR3 Agonist Rintatolimod, (Ampligen®), Accepted for Poster Presentation by Roswell Park Comprehensive Cancer Center at the AACR 2022 Annual Meeting

OCALA, Fla., March 24, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
March 23, 2022 08:05 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest

OCALA, Fla., March 23, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...
March 16, 2022 18:08 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech获美国FDA的IND许可以推进Ampligen®治疗局部晚期胰腺癌的2期研究

迄今为止的数据表明Ampligen®(rintatolimod)可能成为晚期胰腺癌患者系统化疗后的一种潜在的有效维持疗法在一项单中心指定患者用药研究项目中，与未接受Ampligen的对照组相比，在FOLFIRINOX之后配合使用Ampligen治疗与胰腺癌患者的生存率提高相关晚期胰腺癌2期研究预计将于年底前启动佛罗里达州奥卡拉, March 17, 2022 (GLOBE...
March 16, 2022 18:08 ET | Source: AIM ImmunoTech Inc.

AIMイムノテック（AIM ImmunoTech）が米国FDAからIND認可を受け、局所進行膵臓がんの治療におけるAmpligen®の第2相試験へ

これまでに確認されたデータは、アンプリジェン（アンプリゲン）（Ampligen®）（リンタトリモッド（rintatolimod））が進行性膵臓がん患者の全身化学療法後の維持療法として有効である可能性を示している ...
March 16, 2022 07:05 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Ampligen® for the Treatment of Locally Advanced Pancreatic Cancer

Data seen to date indicates that Ampligen® (rintatolimod) could be a potential effective maintenance therapy after systemic chemotherapy in patients with advanced pancreatic cancer In a...
March 09, 2022 16:00 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech宣布《Cancers》特刊《胰腺癌联合和创新疗法》发布晚期胰腺癌早期获取计划（EAP）阳性数据

Ampligen® （rintatolimod）正在荷兰伊拉斯谟医疗中心（Erasmus Medical Center）医疗检查机构批准的早期获取计划（EAP）中作为治疗胰腺癌患者的单药疗法接受评估与未接受Ampligen的对照组相比，在FOLFIRINOX之后配合使用Ampligen治疗与胰腺癌患者的生存率提高相关针对局部晚期胰腺癌患者的2期研究预计将于2022年第二季度/第三季度开始 ...
March 09, 2022 07:35 ET | Source: AIM ImmunoTech Inc.

AIM ImmunoTech Announces Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the AACR 2022 Annual Meeting

OCALA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE: American AIM) (“AIM” or the “Company”), an immuno-pharma company focused on the research and development of therapeutics to...